Compare Gilead Sciences, Inc. (GILD) vs HCA Health Inc (HCA) Price & Performance

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

HCA Healthcare trades at $413.36, up 1.09% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $449.93. The company reported strong Q2 2026 earnings of $7.59 per share, beating estimates, and has shown consistent revenue growth, reaching $75.60 billion in 2025. Recent corporate actions include dividend payments of $0.78 per share, while news highlights executive appointments and ongoing legal investigations.

The stock presents a compelling investment case with attractive valuation multiples like a P/E of 13.86 and robust profitability, but faces risks from legal probes and high debt levels. Upside potential is supported by analyst optimism and solid operational cash flow, though investors should monitor expense pressures and regulatory developments.